Bulletin from the Annual General Meeting
2 November, 2026
Today, November 2, 2026, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority.
Resolution on adoption of the income statement and balance sheet
The AGM resolved to adopt the presented income statement and balance sheet.
Resolution regarding appropriation of the company’s result in accordance with the adopted balance sheet
The AGM resolved to allocate the company’s result in accordance with the Board of Directors’ proposal, and that no dividend be paid for the financial year 2025/2026.
Resolution on discharge from liability for the members of the Board of Directors and the CEO
The AGM resolved to discharge the members of the Board of Directors and the CEO from liability.
Determination of the number of members and deputy members of the Board of Directors
The AGM resolved that the number of members of the Board of Directors shall be five members and that no deputies shall be elected.
Election of Board of Directors and auditor
The AGM resolved to re-elect Andreas Segerros, Per-Olov Asplund, Peter Benson, Rolf Eriksson and Svante Wadman. Andreas Segerros was elected Chairman of the Board.
Azets Revision & Rådgivning AB was elected, with Per Hammar as auditor in charge, as auditor for the period until the end of the next Annual General Meeting.
Determination of fees to be paid to the Board of directors and the auditors
It was resolved that no fees shall be paid to the Board of Directors for the period until the end of the next Annual General Meeting. It was resolved that fees to the auditor shall be paid in accordance with approved invoices.
For further information, please contact:
Gösta Lundgren – CFO
DexTech Medical AB
Phone: +46 (0) 707104788
E-post: gosta.lundgren@dextechmedical.com
The information was submitted for publication, through the agency of the contact person set out above, on November 2, 2026.
DexTech Medical AB is a Swedish research company that, based on its proprietary technology platform, has developed four patented drug candidates.
The company’s lead candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A phase II clinical study with OsteoDex has been conducted with positive results regarding tolerability and treatment efficacy in patients who no longer respond to existing drugs.
OsteoDex has also been evaluated in a clinical phase I/IIa study in multiple myeloma with positive results.
DexTech’s goal is to out-license its drug candidates to commercial partners for continued development and market introduction.